Weekly Investment Analysts’ Ratings Updates for Inspire Medical Systems (INSP)

Several brokerages have updated their recommendations and price targets on shares of Inspire Medical Systems (NYSE: INSP) in the last few weeks:

• 2/18/2026 – Inspire Medical Systems was given a new $60.00 price target by Morgan Stanley.
• 2/13/2026 – Inspire Medical Systems was given a new $67.00 price target by UBS Group AG.
• 2/13/2026 – Inspire Medical Systems was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 2/12/2026 – Inspire Medical Systems had its price target lowered by Royal Bank Of Canada from $90.00 to $68.00. They now have a “sector perform” rating on the stock.
• 2/12/2026 – Inspire Medical Systems was given a new $95.00 price target by Stifel Nicolaus.
• 2/12/2026 – Inspire Medical Systems was given a new $70.00 price target by Wells Fargo & Company. They now have an “equal weight” rating on the stock.
• 2/12/2026 – Inspire Medical Systems was given a new $74.00 price target by Robert W. Baird. They now have a “neutral” rating on the stock.
• 2/12/2026 – Inspire Medical Systems was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $70.00 price target on the stock, down from $145.00.
• 2/12/2026 – Inspire Medical Systems was downgraded by Robert W. Baird from “outperform” to “neutral”. They now have a $74.00 price target on the stock, down from $130.00.
• 2/12/2026 – Inspire Medical Systems had its price target lowered by Jefferies Financial Group Inc. from $81.00 to $66.00. They now have a “hold” rating on the stock.
• 2/12/2026 – Inspire Medical Systems had its price target lowered by Mizuho from $130.00 to $85.00. They now have an “outperform” rating on the stock.
• 2/12/2026 – Inspire Medical Systems had its price target lowered by Truist Financial Corporation from $96.00 to $70.00. They now have a “hold” rating on the stock.
• 2/12/2026 – Inspire Medical Systems had its price target lowered by Piper Sandler from $165.00 to $85.00. They now have an “overweight” rating on the stock.
• 1/27/2026 – Inspire Medical Systems was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $90.00 price target on the stock, down from $175.00.
• 1/22/2026 – Inspire Medical Systems was given a new $96.00 price target by UBS Group AG.
• 1/22/2026 – Inspire Medical Systems had its “outperform” rating reaffirmed by Evercore Inc. They now have a $125.00 price target on the stock.
• 1/22/2026 – Inspire Medical Systems was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $96.00 price target on the stock.
• 1/22/2026 – Inspire Medical Systems was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”.
• 1/14/2026 – Inspire Medical Systems had its price target lowered by Wells Fargo & Company from $160.00 to $145.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Inspire Medical Systems had its price target lowered by Truist Financial Corporation from $165.00 to $120.00. They now have a “buy” rating on the stock.
• 12/29/2025 – Inspire Medical Systems had its “sell (d)” rating reaffirmed by Weiss Ratings.

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.